Strategy analysis

Rheumatoid Arthritis KOL Interview – UK

A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

Rheumatoid Arthritis KOL Interview – New Jersey, US

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

Rheumatoid Arthritis KOL Interview – New Jersey, US

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

Rheumatoid Arthritis KOL Interview – California, US

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

Retinal Disorders (AMD and DME) Pulse

We performed a 5-question survey of 20 ophthalmologists who treat retinal diseases to gauge current usage and projected future usage of agents for the treatment of wet and dry age-related macular degeneration (AMD) and diabetic macular edema (DME).

October 27, 2014

Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #2

This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

December 22, 2021

Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #1

This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

December 22, 2021

Atopic Dermatitis and Psoriasis KOL Interview – US, Southeast

Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #1

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

November 18, 2021

Respiratory Syncytial Virus (RSV) Prevention KOL Interview – UK

This interview with a UK-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

December 22, 2021

Renal Cell Carcinoma KOL Interview – US, Southeast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for renal cell carcinoma. Disease stratifications by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Opdivo, Cabometyx, Keytruda, Inlyta, Lenvima, and Tecentriq.

May 13, 2020

Renal Cell Carcinoma KOL Interview – UK

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for renal cell carcinoma. Disease stratifications by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Opdivo, Cabometyx, Keytruda, Inlyta, Lenvima, and Tecentriq.

May 13, 2020

Renal Cell Cancer Pricing, Reimbursement, and Access

There is moderate concern among payers regarding spend on renal cell cancer (RCC) drugs, but access restrictions remain mild.

August 22, 2018

Regenerative Medicine Landscape

The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status pathway for regenerative medicine advanced therapies.

July 21, 2017

R&D Trends 2016

Over the nine-year period from 2006 to 2014, the Big Pharma, Mid Pharma, and Japan Pharma peer sets collectively spent an annual average of $94bn on R&D of pharmaceuticals, with spending growing at a compound annual growth rate (CAGR) of 6%.

Q4 2016 Outlook Report

$750.00

In this report, we cover catalysts from 23 drugs, devices and diagnostics expected to occur in Q4 2016. We have also included a list of Large Impact catalysts in the drug and device/diagnostic areas through Q4 2016.

November 16, 2016

Pulmonary Hypertension KOL Interview – US #2

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Tyvaso, Tyvaso DPI, Yutrepia, Letairis, Opsumit, Uptravi, Remodulin, Adcirca, sotatercept, INOpulse, and ralinepag.

Pulmonary Hypertension KOL Interview – US #1

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Tyvaso, Tyvaso DPI, Yutrepia, Adempas, Letairis, Opsumit, Orenitram, Uptravi, Remodulin, Adcirca, sotatercept, INOpulse, and ralinepag.

Pulmonary Hypertension KOL Interview – Germany

This interview with a Germany-based key opinion leader (KOL) provides insights into current prescribing habits on- and off-label in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Uptravi, Opsumit, Tyvaso, Remodulin (and Remunity), Adcirca, INOpulse, and sotatercept.

Pulmonary Hypertension KOL Interview – France

This interview with a France-based key opinion leader (KOL) provides insights into current prescribing habits on- and off-label in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Uptravi, Opsumit, Tyvaso, Remodulin (and Remunity), Adcirca, Ventavis, Veletri, Flolan, Revatio, Letairis, INOpulse, and sotatercept.

Psychiatry KOL Insight Interview

At SfN, they showed some interesting preclinical data on the affect on the 5-HT7 and how it works in some animal models of cognition…especially those injected with PCPA. And you know in depression, they also did what we call the chronic mild stress (CMS)

January 24, 2014

Psoriatic Arthritis: Market Access Pricing & Reimbursement

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market.

Psoriasis Pricing, Reimbursement, and Access

Launch of multiple IL inhibitors with impressive efficacy has significantly reduced unmet need in the disease, and also provided payers with leverage in price negotiations as they seek to control growing treatment cost.

March 28, 2019

prostate-cancer-pricing-reimbursement-and-access_162106_10-2016

Prostate Cancer: Market Access Pricing & Reimbursement

The prostate cancer market has become saturated in the metastatic castration-resistant prostate cancer (CRPC) setting; the approval of second-generation antiandrogens, radiotherapies, and chemotherapies has resulted in a great deal of development targeting earlier stages of the disease.

June 1, 2018

Prostate Cancer KOL Interview – US, Northeast #2

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, Lutetium 177Lu-PSMA-617, and CAN-2409.

Prostate Cancer KOL Interview – US, Northeast #1

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, and Lutetium 177Lu-PSMA-617.

Prostate Cancer KOL Interview – US

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Diagnostic testing and unmet needs are also discussed. Key pipeline assets highlighted include Keytruda, Tecentriq, ipatasertib, DCVAC/PCa, capivasertib, Lutetium 177Lu-PSMA-617, and Cabometyx.

November 10, 2020

Prostate Cancer KOL Interview – UK #2

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, and Lutetium 177Lu-PSMA-617.

Prostate Cancer KOL Interview – UK #1

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, and Lutetium 177Lu-PSMA-617.

Profitability Assessment of Branded Generic Inhalers

We set out to examine the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic and generic inhaled products.

October 31, 2016

Product Launch and Commercialization Strategies

Recent years have seen changes in the marketplace that have made successful new drug launches difficult to achieve. Many therapy areas are becoming hypercompetitive, with similar treatments jostling for position, and even those products with evidence of superior efficacy or better tolerability still have to overcome reimbursement hurdles.

December 12, 2016

Precision Medicine and the Future of Healthcare

Precision medicine is typically associated with the use of therapies that target particular disease-linked genetic mutations, identified via a diagnostic test.

October 14, 2016

Post-EASL KOL Interview

Highlights KOL believes elsbasvir and grazoprevir data will lead to approval and look similar to available drugs on the market (MRK). Post-liver transplant data for sofosbuvir and simpeprevir was positive (GLD, JNJ). Three DAA combination of -5816,-9857, and sofosbuvir looked good, but most physicians are erring on the side of conservative 12- week treatment regimens […]

May 29, 2015

Post-EASL KOL Insight Interview

The European Association for the Study of the Liver (EASL) held the 2014 International Liver Meeting in
London from April 9-13. The main focus of this year’s meeting was the clinical use of currently approved and
soon-to-be approved, direct-acting antivirals for Hepatitis C.

May 6, 2014

Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey

Biomedtracker conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom) neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.

March 9, 2017

Post-CHDI Huntington’s Disease KOL Interview

$799.00

Indications: Huntington’s Disease, Alzheimer’s Disease Physician Information Specialty: Neurology Location: London, United Kingdom

March 16, 2015

Post-ADPD Alzheimer’s Disease KOL Interview

Key Highlights BIIB-037 Amyloid beta PET data show positive Abeta reduction; cognitive results are not interpretable with such small numbers. (BIIB) BIIB-037 Phase Ib result interpretation may be effected by the ApoE4 dropouts in the treatment arm. (BIIB) MK-8931 and BIIB-037 show sufficient target engagement, but there is no evidence to date that amyloid clearance […]

April 8, 2015

Post-AASLD US KOL Interview

Over 95% SVR for easy-to-treat patients, and it’s one pill a day for 8-12 weeks for most. In that context, the only way you can improve up on that is to improve care for all populations, not just for easy-to-treat but the difficult-to-treat: decompensated cirrhotics, the post-transplant, and HIV co-infected patients.

December 16, 2014

Post-AAIC KOL Interview

Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial.

August 6, 2014

Poland Pricing and Reimbursement

The average drug price in Poland is the lowest in the EU, mainly due to the high proportion of generic pharmaceuticals, low availability of innovative drugs, and high price pressure on reimbursed drugs.

November 4, 2016

Pneumococcal Vaccines KOL Interview

Datamonitor interviewed three infectious diseases specialists to determine the physicians’ views on marketed and pipeline pneumococcal vaccines. Two physicians were based in Chicago, IL and one in the UK. The three interviews were combined into a single report.

August 27, 2016

Pharma’s Patient Centricity

Patient centricity is the buzzword of this decade, and necessarily so: it either underpins, or is an inevitable result of, all the forces shaping today’s rapidly evolving healthcare landscape.

Pharma-Payer Partnerships in Emerging Markets

Payer partnerships are becoming widespread as emerging markets become wealthier, but access challenges remain. Partnerships with proven success include “strategic philanthropy,” patient access programs, tiered pricing, and service support models.

July 26, 2017

Pharma Externalization Strategies 2016: Externalization is Critical to Pharma Revenue

Pharmaceutical companies constantly re-assess their pipelines and portfolios to determine the best strategies for their business.

Pediatric Epilepsy KOL Interview – US, West

A US expert in pediatric epilepsy provides insight into the approach to treating different forms of epilepsy. The key opinion leader (KOL) dives into the late-phase pipeline for epilepsy, as well as sharing insight into Epidiolex.

February 18, 2019